The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Bladder cancer is often treated by removing visible tumors and using a type of immunotherapy called BCG, delivered through a ...

First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival ...

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, reducing disease progression or death risk by 60%. The EV-303/KEYNOTE-905 trial ...

A 63-year-old cancer patient died after he was prescribed too much morphine in hospital. Paulino Amico’s death was hastened ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial Adding one year of IMFINZI treatment ...

For decades, immune-based cancer therapies have offered hope but also risk, with powerful tumor-fighting effects often ...

Cancer mortality rates continue to fall in Canada, driven by decreases in the death rates from lung and colorectal cancer, ...

Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca’s IMFINZI ® (durvalumab) to BCG induction and maintenance therapy demonstrated a statistically ...